Acurx Pharmaceuticals (ACXP) News Today → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free ACXP Stock Alerts $2.45 +0.12 (+5.15%) (As of 03/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineQ1 2024 EPS Estimates for Acurx Pharmaceuticals, Inc. Decreased by Analyst (NASDAQ:ACXP)americanbankingnews.com - March 22 at 1:48 AMAcurx Pharmaceuticals, Inc. Forecasted to Earn FY2028 Earnings of ($4.13) Per Share (NASDAQ:ACXP)americanbankingnews.com - March 21 at 2:52 AMAcurx Pharmaceuticals, Inc. (ACXP) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 20 at 5:48 PMHC Wainwright Lowers Acurx Pharmaceuticals (NASDAQ:ACXP) Price Target to $12.00americanbankingnews.com - March 20 at 5:58 AMAcurx Pharmaceuticals: Strong Buy on Ibezapolstat’s Promising Phase 3 Trials and Strategic Partnershipsmarkets.businessinsider.com - March 19 at 5:33 PMAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 19 at 12:32 PMQ4 2023 Acurx Pharmaceuticals Inc Earnings Callfinance.yahoo.com - March 19 at 2:31 AMACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023investorplace.com - March 18 at 10:01 AMWe Think Acurx Pharmaceuticals (NASDAQ:ACXP) Needs To Drive Business Growth Carefullyfinance.yahoo.com - March 18 at 9:48 AMAcurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Updateprnewswire.com - March 18 at 7:01 AMAcurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Updateprnewswire.com - March 4 at 7:01 AMAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Developmentfinance.yahoo.com - February 27 at 10:48 AMAcurx Announces FDA Has Granted an End of Phase 2 Meeting for Ibezapolstat for C. difficile Infection and the European Medicines Agency Granted SME Designation for Ibezapolstat EU Developmentprnewswire.com - February 27 at 7:01 AMACXP Mar 2024 4.000 callfinance.yahoo.com - February 17 at 10:06 AMACXP Mar 2024 5.000 putfinance.yahoo.com - February 16 at 11:51 PMNew to The Street Announces its 553rd Episode TV Line Up, Featuring Five Corporate Guests, Airing on the FOX Business Network, Monday, February 5, 2024, 10:30 PM PTfinance.yahoo.com - February 2 at 9:38 AMNew to The Street TV Announces Episode #552 with its Five Business Guest Interviews, Airs on Bloomberg TV as Sponsored Programming, Tonight, February 1, 2024, at 9:30 PM PTfinance.yahoo.com - February 1 at 1:11 PMNew to The Street Announces Episode 551, Five Corporate Interviews, Airing on the FOX Business Network, Monday, January 29, 2024, at 10:30 PM PTfinance.yahoo.com - January 26 at 2:48 PMAcurx Pharmaceuticals to Present at the Microcap Conference, January 31, 2024 - February 1, 2024finance.yahoo.com - January 23 at 8:30 AMAcurx stock plunges 26% amid Phase 2 data release for C. diff drugmsn.com - January 17 at 2:12 PMELAB, KIND and RLX among pre-market losersmsn.com - January 17 at 9:12 AMAcurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Trialmarkets.businessinsider.com - January 17 at 9:12 AMNew to The Street Announces its Four Corporate Interviews, Episode 543, Airing on the Fox Business Network, Monday, January 8, 2024, at 10:30 PM PTfinance.yahoo.com - January 5 at 1:19 PMAcurx to present at the 42nd Annual J.P. Morgan Healthcare Conferencefinance.yahoo.com - January 3 at 1:26 PMAcurx Pharmaceuticals Stock (NASDAQ:ACXP), Guidance and Forecastbenzinga.com - December 28 at 1:30 AMImpressive Phase 2b Results and Positive Outlook Justify Buy Rating for Acurx Pharmaceuticalsmarkets.businessinsider.com - December 15 at 7:42 PMBuy Rating for Acurx Pharmaceuticals Stemming from Ibezapolstat’s Positive Phase 2b Resultsmarkets.businessinsider.com - December 13 at 8:35 AMWhy Acurx Pharmaceuticals (ACXP) Shares Are Falling Todaymsn.com - December 11 at 2:43 PMNew to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PTfinance.yahoo.com - December 7 at 9:30 AMNew to The Street Announces its Five Business Guest Interviews, Episode 533, Airs on the FOX Business Network on Monday, November 27, 2023, at 10:30 PM PTfinance.yahoo.com - November 24 at 9:58 AMNew to The Street Announces Episode 530 with Six Corporate Interviews, Airing on the Fox Business Network, Monday, November 20, 2023, at 10:30 PM PTfinance.yahoo.com - November 17 at 10:48 AMAcurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 15 at 3:33 PMAcurx Pharmaceuticals: Q3 Earnings Insightsbenzinga.com - November 14 at 8:25 AMAcurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Updatefinance.yahoo.com - November 14 at 8:25 AM12 Best Day Trading Stocks To Buyfinance.yahoo.com - November 9 at 10:22 AMBuy Rating on Acurx Pharmaceuticals: Promising Clinical Results and Financial Stability Highlighted by Analyst Ed Arcemarkets.businessinsider.com - November 3 at 7:19 AMAcurx Pharma falls after mid-stage data for lead assetmsn.com - November 2 at 8:55 PMAcurx Pharmaceuticals (ACXP) Price Target Increased by 8.82% to 12.58msn.com - November 2 at 10:40 AMAcurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infectionfinance.yahoo.com - November 2 at 10:40 AMAcurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Updatefinance.yahoo.com - October 25 at 9:54 AMAcurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferencesfinance.yahoo.com - October 19 at 8:16 AMWhat's Going On With Acurx Pharmaceuticals Inc Stock Today?benzinga.com - October 18 at 2:34 PMWhat's Going On With Acurx Pharmaceuticals Stock Now?benzinga.com - October 12 at 2:42 PMmarketbeat.com - October 12 at 12:35 PMmarketbeat.com - October 12 at 12:14 PMmarketbeat.com - October 12 at 12:07 PMWhat's Going On With Acurx Pharmaceuticals Stock?benzinga.com - October 9 at 6:10 PMAnalysts Offer Insights on Healthcare Companies: PDS Biotechnology (PDSB) and Acurx Pharmaceuticals (ACXP)markets.businessinsider.com - October 2 at 1:17 PMAcurx Pharma Discontinues Phase 2b Trial For Ibezapolstat To Treat C. Difficile Infectionmarkets.businessinsider.com - October 2 at 8:17 AMAcurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infectionfinance.yahoo.com - October 2 at 8:17 AM Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem. Protect your retirement savings from the inevitable devaluation of the dollar… ACXP Media Mentions By Week ACXP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACXP News Sentiment▼0.260.60▲Average Medical News Sentiment ACXP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACXP Articles This Week▼51▲ACXP Articles Average Week Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Theratechnologies News Alaunos Therapeutics News FSD Pharma News Sol-Gel Technologies News VYNE Therapeutics News Orgenesis News Spruce Biosciences News CytoMed Therapeutics News Sensei Biotherapeutics News eFFECTOR Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACXP) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryFed launches fourth dollar overhaulStansberry ResearchBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the MarketsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.